Skip to main content
Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway.
Published Web Location
http://europepmc.org/articles/PMC4484434?pdf=renderNo data is associated with this publication.
Abstract
KRAS is mutated in about 20-25% of all human cancers and especially in pancreatic, lung and colorectal tumors. Oncogenic KRAS stimulates several pro-survival pathways, but it also triggers the trans-activation of pro-apoptotic genes. In our work, we show t
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.